Celltrion Says New Data Prove Remsima SC Is A ‘Biobetter’

Subcutaneous Infliximab Shows Improved Outcomes Compared To Intravenous Version

 
• By David Wallace
  
Better word clouds
Celltrion’s subcutanous infliximab performed better than the intravenous version • Source: Shutterstock
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Products